InvestorBrandNetwork (IBN) Content Platform

CISO Global Inc. (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider, has been listed on PCI Marketplace as a PCI Quality Security Assessor (“QSA”). The distinction means that CISO Global is certified and authorized by the Payment Card Industry Security Standards Council (“PCI SSC”) to assess and validate the compliance of organizations with Payment Card Industry Data Security Standard (“PCI DSS”). PCI DSS is a set of security standards that works to protect the confidentiality and integrity of credit-card and payment-card data. CISO Global works with clients to assist them as they transition to upcoming PCI 4.0 standards, performing security assessments to verify PCI DSS compliance.

The company has expanded its team of PCI assessors to meet growing client needs as organizations start on the process of becoming compliant with the “heftier” requirements. CISO Global provides several levels of services that include On-site Assessment and Remediation Services, PCI Gap Assessment Services and External PCI ASV Scanning Service, as well as Governance, Risk and Compliance (GRC) Tracking. “We are committed to helping the industry meet the increasing list of regulatory requirements as seamlessly as possible,” said CISO Global CEO David Jemmett in the press release. “Our teams are focused on meeting these soon-to-be critical requirements for increased standards and practices to secure credit card data and better protect merchants and their customers so they can continue to operate their businesses without interruption.”

To view the full press release, visit https://ibn.fm/nOOJ0

About CISO Global Inc.

CISO Global is an industry leader as a managed cybersecurity and compliance provider. The company is rapidly expanding by acquiring world-class cybersecurity, secured managed services and compliance companies with top-tier talent that utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and compliance obligations. For more information about the company, visit www.CISO.inc.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a human factor study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (“PTSD”). According to the announcement, the study will evaluate the human factor interface and usability of SPC-15’s intranasal formulation in combination with a nose-to-brain delivery mechanism. “The human factor study is an important step as we prepare and plan to enter the clinic with SPC-15 for the treatment of PTSD and stress-related disorders,” said Eric Weisblum, chief executive officer of Silo Pharma. “The first of the two-part study was launched in October, with the expected completion of this study before year end 2023.”

To view the full press release, visit https://ibn.fm/lU0vE

About Silo Pharma Inc.

Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which it believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today announced that its flagship daytime-nighttime appliance (“DNA”) will be tested in a clinical trial at Stanford Medicine. According to the update, the protocol has been finalized and participant enrollment will begin in early 2024. “In a retrospective review of 220 patients*, we have seen that Vivos’ oral appliance therapy decreases the apnea-hypopnea index (‘AHI’) while increasing airway volume. The median reduction in AHI was 49% in this cohort and a quarter of patients resolved their OSA completely. These end results were measured after a 12-18 month course of therapy without the appliance in the mouth – meaning the effects persisted while not using treatment – something not seen with CPAP,” said Cecilia Wu MD, co-chair of the clinical advisory board at Vivos Therapeutics. “While Vivos believes in these results, it is important to apply the highest standards in medical research in the form of a prospective randomized controlled trial. This will truly test Vivos’ treatment to the same standard as all other modalities.”

To view the full press release, visit https://ibn.fm/eV3xk

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild-to-moderate OSA. It has proven effective in approximately 40,000 patients treated worldwide by more than 1,800 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using The Vivos Method. For more information, visit www.Vivos.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

*Katz D, Demaria S, Heckman S, Lin F, Kushida C. Use of the Complete Airway Repositioning and Expansion (CARE) approach in 220 patients with Obstructive Sleep Apnea (OSA): A retrospective cohort study. Sleep Med. 2022 Nov;99:18-22.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Zevra Therapeutics (NASDAQ GS: ZVRA), a rare-disease therapeutics company, has named Neil F. McFarlane as president and CEO; McFarlane will also serve on the company’s board of directors. The new appointments are effective immediately. According to the announcement, Christal M.M. Mickle, who has been serving as interim CEO and president since June, will continue serving in her role as chief development officer. A former officer and enlisted soldier in the United States Army Reserves, McFarlane has an impressive, results-driven track record as a biopharmaceutical leader with proven ability to accelerate Zevra’s strategy of melding science, data and patient needs to create transformational therapies for patients with rare diseases. Throughout his two-decade-plus career, he has delivered sustained growth in a range of specialty and rare-disease products around the world, including the United States, Europe, Asia and Latin America. Most recently, he served as CEO and board member at Adamas Pharmaceuticals Inc. He has also worked at Retrophin Inc. (now Travere Therapeutics, Inc.), UCB Inc., Genzyme Corporation (now Sanofi) and Sangstat Medical Corporation (acquired by Genzyme). Zevra also announced the effectiveness of Joseph B. Saluri’s retirement from the board of directors.

“Neil’s appointment as president and chief executive officer is the culmination of a thorough process undertaken by the board of directors and comes at a pivotal time for our company,” said Zevra Therapeutics board chair Tamara A. (Seymour) Favorito in the press release. “His successful track record of leading innovative companies through periods of strategic change, and enhancing value to patients, employees and shareholders will be of tremendous importance to Zevra as we deliver much-needed therapies to the rare-disease community. We have great confidence in his ability to shepherd our company through the next phase of our journey. In addition, we appreciate Christal’s contributions to Zevra during this important time and look forward to her continued contributions. We also extend our sincere gratitude to Joe Saluri for his significant contributions to the company as a board member. He has played an integral part in advancing the company’s mission and bringing valuable expertise throughout its entire existence as a public company.”

To view the full press release, visit https://ibn.fm/knMD3

About Zevra Therapeutics

Zevra Therapeutics is a rare-disease company melding science, data and patient need to create transformational therapies for diseases with limited or no treatment options. With unique, data-driven clinical, regulatory and commercialization strategies, the company is overcoming complex drug-development challenges to bring much-needed therapies to patients. With both regulatory and clinical stage product candidates, Zevra Therapeutics is building its commercial capability to make new therapies available to the rare disease community. For more information about the company, please visit www.Zevra.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Safety Shot (NASDAQ: SHOT) today announced that Jarrett Boon, who has served as the company’s chief operating officer since August 2023, has been appointed to Safety Shot’s board of directors. Boon is leading the launch and growth of the company’s Safety Shot functional drink business this quarter. Boon was the co-founder and CEO of GBB Drink Lab, which developed Safety Shot, the first patented beverage that helps people feel better faster by reducing blood alcohol content and boosting clarity. “In the past few months since I’ve joined the company, our outstanding team has teed up the Safety Shot drink for launch this last quarter of 2023 and built market momentum for direct-to-consumer sales,” said Safety Shot’s COO Jarrett Boon. “I couldn’t be more excited about the potential for Safety Shot to improve health and wellbeing for consumers. I’m pleased to become a member of the board to guide our corporate direction and deliver solid results for all our stakeholders including Safety Shot shareholders.”

To view the full press release, visit https://ibn.fm/hah3n

About Safety Shot Inc.

Safety Shot, a wellness and functional beverage company, is set to launch Safety Shot the last quarter of 2023, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting brain clarity. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://jupiterwellness.com/email-alerts.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Pressure BioSciences (OTCQB: PBIO) (“PBI”) is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and specialty process development and testing services to the global pharmaceuticals, nutraceuticals, cosmeceuticals, food/beverage and other industries. The company today announced the award of the first Canadian patent for its revolutionary UltraShear(TM) Technology (“UltraShear(TM)” or “USTTM”) platform. “Nanoemulsions have long been shown to exhibit improved absorption, higher bioavailability and greater stability, while often requiring lower levels of emulsifiers than macro/micro emulsion products,” said Dr. Edmund Y. Ting, SVP of Engineering of PBI and the inventor on this patent. “Because of these significant advantages, nanoemulsions are currently the focus of numerous research efforts worldwide. However, cost-effective scale-up of high quality nanoemulsion processing at a commercial level has long remained to be quite challenging. Importantly, we believe that PBI’s innovative, patented and now Canadian patent-protected UltraShear platform will provide the pivotal key to commercial success for nanoemulsion products.”

To view the full press release, visit https://ibn.fm/ae9Hm

About Pressure BioSciences Inc.

Pressure BioSciences is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Its products utilize both constant and alternating pressure. The company’s patented enabling technology platform, Pressure Cycling Technology (“PCT”), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterrorism applications. The company has recently expanded its market opportunities with the acquisition of the BaroFold(TM) patented technology platform, allowing it to enter the bio-pharma contract services and GMP manufacturing equipment sector. The company has also developed the scalable and high-efficiency pressure-based UltraShear Technology(TM) (UltraShear(TM)) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information about the company, visit www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Splash Beverage (NYSE American: SBEV), a portfolio company of leading beverage brands, has entered into a new agreement with Georgia-based Horizon Retailers Association (“HRA”). One of the South’s fastest-growing convenience store retail associations, HRS represents more than 2,500 retailers and 20 major vendors in the Southeast United States. According to the announcement, HRA is adding SBEV’s TapouT Energy Drink to its fall planogram, which is available to all participating stores, and will include three “facings” in its Energy Drink category, one for each TapouT flavor. SBEV noted that this new agreement with HRA is a direct result of its recently signed distribution agreement with United Distributors of Georgia.

“We couldn’t be prouder to announce this agreement,” said Splash Beverage CEO Robert Nistico in the press release. “This is our largest planogramed authorization to date, and [we] believe TapouT Energy Drink will greatly benefit from this level of retail concentration and cold availability for immediate consumption. Our team has been hard at work over the past few months putting all these pieces into place. Splash’s footprint will increase significantly in the southeast with this announcement. This is exciting news as we continue to execute on our distribution and retail strategy. As I discussed a few months ago, this process takes time. We push for distribution, support those efforts with marketing, then start pushing again for more distribution coverage ultimately achieving greater and greater availability.”

To view the full press release, visit https://ibn.fm/M9PbQ

About Splash Beverage Group Inc.

Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and nonalcoholic beverage brands including Copa di Vino wines by the glass, SALT flavored tequilas, Pulpoloco sangrias, and TapouT performance hydration and recovery drinks. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution. For more information about the company, please visit www.SplashBeverageGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Amesite (NASDAQ: AMST), a leading artificial intelligence software company, is expanding its partnership with Michigan Works! Southeast (“MWSE”). According to the announcement, the partnership will result in the launch of 12 new courses this year. The courses will provide training on artificial intelligence technologies and their applications in the modern workplace. These courses will be found on MWSE’s proprietary Learning Community Environment(R) , which is powered by Amesite. Amesite noted that the new courses provide a deep dive into the transformative wave of Industry 4.0 and include modules focused on an array of pertinent topics, including the underpinnings of internet technology, challenges posed by AI in job retention and the innovative use of ChatGPT.

There are even modules that teach students how to write compelling resumes, cover letters and follow-up emails as well as interview strategies and how to optimize their online job search. Noting the increase of “new-collar” jobs, an MWSE official observed that the goal of the stronger partnership is to equip community members with the requisite skills for those roles and prepare them for the evolving job landscape of Industry 4.0. “Workforce development agencies have a significant opportunity to leverage modern tools to assist individuals in their growth and readiness for the job market, and we are excited to be able to provide critical skills to a multi-billion-dollar market and expect these offerings to be in high demand,” said Amesite founder & CEO Dr. Ann Marie Sastry in the press release. “At Amesite, we’ve focused on creating solutions that easily integrate into existing systems. Our partnership with Microsoft enables us to deploy these tools swiftly, often within a 24-hour window.

To view the full press release, visit https://ibn.fm/OtFRH

About Amesite Inc.

Amesite delivers its scalable, customizable, white-labeled online learning platform to universities, businesses, museums and government agencies, enabling them to deliver outstanding digital learning. Amesite provides a single system that combines eCommerce, instruction, engagement, analytics and administration using best-in-class infrastructure to serve multibillion-dollar online learning markets. For more information about the company, please visit www.Amesite.io.

NOTE TO INVESTORS: The latest news and updates relating to AMST are available in the company’s newsroom at https://ibn.fm/AMST

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Standard Lithium (TSX.V: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial lithium company, today announced that, to the best of its knowledge, it has drilled and sampled a new highest confirmed lithium grade brine in North America, with a grade of 663 mg/L lithium. According to the update, the results reflect lithium sample analyses from a newly drilled well from the company’s significant expansion work in the East Texas Smackover region. “We continue to be very excited by the quality and scale of the lithium brine assets we’re adding in East Texas,” said Dr. Andy Robinson, president and COO of Standard Lithium. “The lithium sample analysis from a newly-drilled well delivered, to the best of our knowledge, a new highest-grade lithium brine concentration in North America and confirmed that we are securing the highest-grade lithium brine resource outside of Chile and Argentina. We continue to expand our footprint in the East Texas Smackover and de-risk the opportunity with additional drilling, sampling and definition work.”

To view the full press release, visit https://ibn.fm/mosAL

About Standard Lithium Ltd.

Standard Lithium is a leading near-commercial lithium development company focused on the sustainable development of a portfolio of lithium-brine bearing properties in the United States. The company prioritizes brine projects characterized by high-grade resources, robust infrastructure, skilled labor, and streamlined permitting. The company aims to achieve sustainable, commercial-scale lithium production via the application of a scalable and fully integrated direct lithium extraction (“DLE”) and purification process. The company’s flagship projects, the Phase 1A and the South West Arkansas projects, are located on the Smackover Formation in southern Arkansas near the Louisiana state line, a region with a long-standing and established brine processing industry. The company has also identified a number of highly prospective lithium brine project areas in the Smackover Formation in East Texas and began an extensive brine leasing program in the key project areas. In addition, the company has an interest in certain mineral leases located in the Mojave Desert in San Bernardino County, California. Standard Lithium trades on both the TSX Venture Exchange and the NYSE American under the symbol SLI and on the Frankfurt Stock Exchange under the symbol S5L. For more information, please visit the company’s website at www.StandardLithium.com.

NOTE TO INVESTORS: The latest news and updates relating to SLI are available in the company’s newsroom at https://ibn.fm/SLI

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

SenesTech (NASDAQ: SNES), animal pest fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, will be participating in this month’s Lytham Partners Fall 2023 Investor Conference; the conference is slated for Oct. 17, 2023. According to the announcement, SenesTech CEO Joel Fruendt and CFO Tom Chesterman will present during the elite event. Their presentation is scheduled to begin at 7 a.m. ET. In addition, the two company officials will be available to host one-on-one meetings with investors.

To view the presentation, visit https://ibn.fm/wCnRR or https://ibn.fm/42I3F

To view the full press release, visit https://ibn.fm/Gkucz

About SenesTech Inc.

SenesTech is committed to being “the pest-control difference” for the 21st century. The company’s passion is to create a healthy environment by virtually eliminating rodent pest populations. The company keeps an inescapable truth in mind: two rats and their descendants can be responsible for the birth of up to 15,000 pups after a year. SenesTech invented ContraPest, the only U.S. EPA-registered contraceptive for male and female rats. ContraPest fits seamlessly into all integrated pest-management programs, greatly improving the overall goal of effective rat management. The company strives for clean cities, efficient businesses and happy households — with a product that was designed to be effective and sustainable without killing rats. For more information about the company, please visit www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has completed its admission to the Access segment of the AQSE Growth Market; the company begins trading on today at market open. According to the announcement, Mydecine will have a dual listing with its common shares fully fungible through a CREST Depositary Interest (“CDI”); the company will be classified as a healthcare company on the access segment of the Aquis Stock Exchange.

 In the announcement, the company noted that its various families of novel second-generation molecules are showing significant improvements over the first generation of psychedelic treatments. Mydecine is currently working with a preclinical team at the University of Alberta to work these molecules through the Investigational New Drug enabling stage with plants to begin human clinical trials in 2024. Mydecine’s comprehensive intellectual property strategy covers novel molecules, drug formulations, delivery mechanisms and methods of production. “We are incredibly excited to list our securities for trading in the UK on the AQSE Growth Market,” said Mydecine Innovations CEO Josh Bartch in the press release. “We believe Mydecine is at a pivotal phase in its development and look forward to increased exposure to UK and European investors alike.”

To view the full press release, visit https://ibn.fm/WzWJV

About Mydecine Innovations Group Inc.

Mydecine Innovations is a publicly traded, prerevenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians’ access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction and PTSD, along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (“AI”). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations. Mydecine developed several prodrug families, beginning with a psilocybin-derived smoking cessation drug  undergoing an NIDA-funded trial at Johns Hopkins University. The company is also developing MYCO-006, short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. Mydecine utilizes cutting-edge AI and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make those medications affordable and accessible to the general public upon Health Canada and FDA approval. The Mydecine team is enthusiastic about its mission and is dedicated to creating a positive difference in the lives of others. For more information about the company, please visit www.Mydecine.com.

NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Siyata Mobile (NASDAQ: SYTA, SYTAW), a global vendor of Push-to-Talk over Cellular (“PoC”) devices and cellular signal booster systems, has been invited to present at Maxim Group LLC’s Exploring All Corners of the Tech Sector conference. The event is scheduled for Oct. 10–11, 2023, and will be live on M-Vest. According to the announcement, during the event, Maxim senior analysts will facilitate engaging dialogues with executives and key team members of a variety of tech-focused companies. “Our company will be taking part in the Virtual Tech Conference Series: Exploring All Corners of the Tech Sector,” stated the company in the press release. “The continuous evolution of technology is paving the way for innovations across all industries, including financial services, esports, iGaming, entertainment and more. In the second installment of the 2023 Virtual Tech Conference, participants will explore how emerging growth companies are leveraging new technologies to position themselves for the future.”

To view the full presentation, visit https://ibn.fm/jeVJI

To view the full press release, visit https://ibn.fm/0DeyF

About Siyata Mobile Inc.

Siyata Mobile is a B2B global vendor of next-generation, Push-to-Talk over cellular handsets and accessories. Its portfolio of rugged PTT handsets and accessories enables first responders and enterprise workers to instantly communicate over a nationwide cellular network of choice, to increase situational awareness and save lives. Police, fire and ambulance organizations as well as schools, utilities, security companies, hospitals, waste-management companies, resorts and many other organizations use Siyata PTT handsets and accessories. In support of Siyata’s Push-to-Talk handsets and accessories, the company also offers enterprise-grade, in-vehicle solutions and cellular booster systems enabling its customers to communicate effectively when they are in their vehicles, even in areas where the cellular signal is weak. Siyata sells its portfolio through leading North American cellular carriers, as well as through international cellular carriers and distributors. For more information about the company, visit www.SiyataMobile.com or www.UnidenCellular.com.

NOTE TO INVESTORS: The latest news and updates relating to SYTA are available in the company’s newsroom at http://ibn.fm/SYTA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Large, mid-size and small pharma companies are invited to attend the 18th Biopharma Medical Affairs Nexus being held October 17-18, 2023, in Philadelphia. The event will focus on networking and the flow of important data in key areas of Medical Affairs, Medical Operations, Medical Excellence, MSL, Medical Communications, Scientific Affairs, Field Medical, Medical Education, Clinical Investigation, Business Intelligence, and Medical Science.

The event is hosted by BioPharma Nexus, a premier company organizing top-notch conferences that develop and strengthen ties between pharmaceutical and biotech companies, along with the service providers. They strive to offer the best-quality healthcare and medication to patients all over the…

Read More>>

To know more, please visit https://ibn.fm/22ZJE.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The company’s lead program NRX-101, an oral, fixed-dose combination of D-cycloserine (“DCS”) and lurasidone, targets the brain’s N-methyl-D-aspartate (“NMDA”) receptor and is being investigated in a Phase 2b/3 clinical trial for suicidal treatment-resistant bipolar depression (S-TRBD), which includes patients with both acute and sub-acute suicidality, an indication for which the only approved treatment is electroshock therapy. The company has partnered with Alvogen Pharmaceuticals for the worldwide rights to NRX-101 for treatment of S-TRBD, to help bring NRX-101 to a global population of patients with unmet this medical need. NRx Pharmaceuticals is also currently exploring NRX-101’s potential to act as a non-opioid chronic pain treatment option and awaits results from a 200 patient Department of Defense funded study of DCS in low back pain. For more information, visit the company’s website at: www.NRxPharma.com.

To view IBN’s virtual coverage of the conference, visit https://ibn.fm/DawsonJamesConference2023  

About InvestorBrandNetwork’s Virtual Coverage

The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating at the Dawson James Small Cap Growth Conference. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.

For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

MetAlert (OTC: MLRT), a pioneer in GPS wearable technology and global provider in the field of human and asset-tracking and recovery systems, and its wholly owned subsidiary Level 2 Security, announced its first commercial order for the game-changing GunAlert(R) firearm recovery device. The order has been received, and the device has been delivered to the customer, Ohio-based Range USA, which operates more than 40 locations across 10 states. According to the announcement, MetAlert recently acquired level 2 security, which provides motion-detection and GPS technology to detect unauthorized movement or use of firearms and other valuable mobile assets. The company is looking to expand into this space, which has exceptional resources following the announcement by the Office of Justice Programs, which is investing significantly in programs designed to reduce gun crime and community violence.

“We pioneered tracking and monitoring technology for humans with a primary goal of providing safety and peace of mind,” said MetAlert CEO Patrick Bertagna in the press release. “Level 2’s patented technology, which specializes in monitoring unauthorized use and movement of firearms and other valuable mobile assets, is a natural synergistic extension to our product line, and ethos of providing technology that supports saving lives. We are excited about receiving our first commercial order from Range USA, the nation’s leading indoor range & gun store, offering customers the best variety of name brand firearms, gear, supplies and accessories. . . . We expect to play an important role in the national conversation surrounding gun safety, and as part of that effort, we have begun providing police departments and police officers with evaluation units. We plan to work closely with law enforcement to help manage this channel and navigate access to the different federal grant programs currently available, along with working with the media to help bring attention to this game-changing technology when it comes to gun safety.”

To view the full press release, visit https://ibn.fm/7ZzYo

About MetAlert Inc.

MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing and licensing products, services and intellectual property in the GPS/BLE wearable technology, personal location, wandering assistive technology, and health-data collection and monitoring spaces. With more than 20 years of experience and an extensive patent portfolio, MetAlert is a leading solution provider for consumers/patients afflicted with Alzheimer’s, dementia and autism. This market represents approximately 2.9% of the world’s population. The company offers global end-to-end hardware, software and connectivity solutions, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products, enterprise and government agency applications. The company utilizes the latest in miniaturized, low-power consumption GPS, cellular, RF, NFC and BLE technologies, enabling caregivers to track and monitor patients in real-time. The company is known for its game-changing and award-winning patented GPS SmartSole(R) — think Dr. Scholl’s meets LoJack, the world’s first invisible, wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism, and traumatic brain injury. MetAlert’s subscription-based business model is built around technology innovation with intellectual property protection. The company has international distributors servicing customers around the globe with subscribers in more than 40 countries ; the company is also a U.S. military government contractor. Other customers include public health authorities, municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers. For more information about this company, please visit www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Pinon Hill Capital, recognized as a leading force in E-Commerce investment, has launch a new Reg D offering. According to the announcement, the exclusive offering is designed to give accredited investors access to a diversified range of investment avenues within the E-Commerce sector. The company noted in the announcement that its approach involves strategic acquisitions and investment diversification while also providing investors with the tools they need to navigate the ever-evolving landscape of E-Commerce. The offering enables accredited investors to diversify their portfolios by participating in a variety of strategic investments. “In this era of vast investment opportunities, Pinon Hill Capital has emerged as a beacon of innovation and reliability,” said Pinon Hill Capital senior capital markets associate Cole Buller in the press release. “Our mission is to provide accredited investors with a unique pathway to tap into the dynamic world of E-Commerce.”

To view the full press release, visit https://ibn.fm/gd2Y7

About Pinon Hill Capital

Pinon Hill Capital is a pioneer in E-Commerce investment, delivering transformative experiences to accredited investors and changing the game. For more information about this company, please visit www.PinonHillCapital.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTC: PLTXF), the digital face of the plant-based community operating a one-stop shop for plant-based products, has completed the share exchange agreement with Veg House Holdings Inc. According to the announcement, the company closed on the agreement on Oct. 6, 2023; the company said the transaction “signifies a noteworthy stride towards solidifying our enhanced footprint within the expanding domains of plant-based lifestyle and wellness.” Based on the agreement, PlantX transferred a collection of assets in exchange for roughly 50.9% of the total issued and outstanding shares of Veg House at the time of the closing; these assets encompass wholly owned subsidiaries including Vegaste Technologies US Corp., Little West LLC, Plant Based Deli LLC and PlantX Living Inc.

Assets also include the company’s 53% ownership stake in Portfolio Coffee Inc. and 51% ownership in Eh Coffee Corp. In exchange, PlantX acquired six million shares out of the current estimated 11,778,639 outstanding shares in Veg House, resulting in a significant 50.9% ownership stake in the Cayman Islands-based entity. “By means of this share exchange agreement, funds were secured by Veg House at a post-transaction valuation of $11.778 million, based on the most recent private placement price of $1 USD per share, underlining the enduring enthusiasm for the industry and underscoring the significance of this transaction for steadfast supporters of the Canadian company,” said PlantX Life CEO Lorne Rapkin in the press release.

To view the full press release, visit https://ibn.fm/WLj92

About PlantX Life Inc.

PlantX is committed to being the digital face of the plant-based community as well as the one-stop shop for plant-based products. With its fast-growing category verticals, the company offers customers across North America more than 5,000 plant-based products. PlantX also has other brands in the PlantX portfolio, including a juice brand, a coffee company, a plant shop and brick-and-mortar grocery stores. PlantX uses its digital platform to build a community of like-minded consumers and, most importantly, to provide education. PlantX’s digital presence eliminates entry barriers for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information about this company, please visit www.PlantX.com and www.PlantX.ca.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Supply chain professionals, logistics experts, pharmaceutical executives, regulatory affairs specialists, technology and solutions providers, healthcare providers, investors, and government representatives, are all invited to attend the 2nd BioPharma Supply Chain & Logistics Nexus to be held in Philadelphia, PA, October 17-18, 2023. This diverse mix of attendees will get a unique platform for collaboration, knowledge sharing, and networking, ensuring a remarkable event for all those involved in the BioPharma supply chain and logistics ecosystem.

The BioPharma industry has always been a beacon of advancement and unwavering innovation, providing life-saving therapies and medicines to innumerable individuals across the globe. However, it’s important to ensure that these essential medications reach their destination in a timely manner amidst the…

Read More>>

To learn more, please visit https://ibn.fm/RHORL.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Aditxt (NASDAQ: ADTX) is an innovation activation company focused on the discovery, development and deployment of technologies that monitor and modulate the immune system. The company today announced that it will present at the 8th Annual Dawson James Conference on Thursday, Oct. 12, 2023, at the Wyndam Grand Jupiter at Harbourside Place in Jupiter, Florida. Aditxt’s Chief Executive Officer Amro Albanna will deliver the company’s presentation and conduct in-person one-on-one meetings throughout the conference.  Albanna’s presentation is slated to begin at 9 a.m. ET on Oct. 12 in Preserve Ballroom B.

To view the full press release, visit https://ibn.fm/Zo4XH

About Aditxt Inc.

Aditxt is an innovation activation company focused on the discovery, development and deployment of technologies that monitor and modulate the immune system. The company is headquartered in Richmond, Virginia, with operations in Mountain View, California, and Melville, New York. Aditxt’s mission of “Making Promising Innovations Possible, Together” is defined by its growing ecosystem of research institutions, global industry partners and shareholders who inform and inspire its mission. Aditxt’s diverse innovation portfolio includes: Adimune(TM), Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity and allergies; Adivir(TM), Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta(TM), Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at their CLIA certified and CAP accredited clinical laboratory based in Richmond, Virginia. For more information, visit the company’s websites at www.Aditxt.com, www.Adimune.com and www.Pearsanta.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

The Sustainable Green Team (OTCQX: SGTM), a leader in environmentally conscious solutions in the arbor care, disposal and recycling industry, has announced the successful sale of $12 million worth of state-of-the-art equipment as part of a groundbreaking Middle East deal. In addition to the equipment sale, the transaction includes an allocation of $8 million for transportation and reinstallation, bringing the total value to an impressive $20 million. Recently, Sustainable Green Team invoiced approximately $7.5 million from its innovative new product lines, HumiSoil(R) and Core Catalyst, to the Middle East. “We are delighted to be entering into this partnership, which represents a significant milestone for Sustainable Green Team as we continue our strategic transformation,” said Tony Raynor, CEO of Sustainable Green Team. “Our commitment to sustainability drives us to convert underutilized assets into groundbreaking solutions. With our expertise in recycling, we will provide essential knowledge, cutting-edge equipment and sustainable fiber solutions to the Middle East, a region with a tremendous need for soil enhancement.”

To view the full press release, visit https://ibn.fm/60jhH

About Sustainable Green Team Ltd.

The Sustainable Green Team is at the forefront of promoting environmental sustainability through innovative recycling solutions. Committed to preserving and protecting the planet, SGTM specializes in transforming underutilized assets into valuable resources that benefit both the environment and society. With expertise and cutting-edge equipment, SGTM strives to create a greener future for generations to come. For more information, visit the company’s website at www.sustainablegreenteam.com.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be presenting at the Neuropsychiatric Drug Development Summit, slated for Oct. 11–12, 2023, in Boston. Cybin’s abstract, titled “Structure-activity of 2C-X psychedelics to develop a novel 5-HT_2A receptor full agonist with therapeutic potential,” was chosen to be presented during the premier gathering. The presentation is scheduled for Oct. 11, 2023, at 5 p.m. ET. The abstract describes a comprehensive structure-activity relationship study of a series of novel serotonergic phenethylamines and summarized CYBN’s studies that identified multiple potential compounds of therapeutic potential with attractive drug-like characteristics, including good safety profile, high oral bioavailability and brain penetration.

In addition to reporting on the abstract, company officials will also moderate a psychedelic workshop titled, “Making Psychedelic Clinical Trials a Reality: Mitigating Practical Burdens of Time, Investment & Reimbursement.” The workshop will begin at 9 a.m. ET on Oct. 10, 2023. The workshop will include topics such as optimizing clinical trial design, addressing the need for monitoring in psychedelic trials, and the potential therapeutic advantages and durability of short-acting psychedelic compounds. “We are extremely pleased that our abstract was selected for presentation, as this is foundational research that will inform the selection of a potential future development candidate,” said Cybin CEO Doug Drysdale in the press release. “The Neuropsychiatric Drug Development Summit is a unique opportunity to engage with innovators in neuropsychiatry and to share ideas that ultimately drive the field forward.”

To view the full press release, visit https://ibn.fm/JRheH

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental-health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Cannabis enthusiasts, investors, decision-makers, and business owners, are invited to attend the 18th BioPharma Clinical Trials Nexus to be held in Philadelphia, PA, October 17-18, 2023. The innovative event is set to ignite the spirit of collaboration that transcends disciplines. and borders. It stands as a paradigm for actionable change in the world of clinical research and pharmaceuticals.

The BioPharma Clinical Trials Nexus will feature thought-provoking seminars and sessions where visionaries will share their ideas and perspectives about the key challenges in clinical research and pharmaceutical development. Led by industry veterans, the seminars will focus on discussing the…

Read More>>

To learn more, please visit https://ibn.fm/t8n6m.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Mydecine Innovations (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has received approval to list its common shares on the Canadian Securities Exchange (“CSE”). The company therefore submitted a request to the NEO Exchange Inc., operating as Cboe Canada, to delist its common shares, under the symbol NEO. According to the announcement, that delisting took place on Oct. 5, 2023, at market close. With market opening today, Mydecine common shares are expected to begin trading on the CSE under the symbol MYCO. “Management is excited about the listing of the common shares on the CSE and the opportunities it provides to its investors, as the company continues the ongoing development of its business operations,” said the company in the press release. “In addition, the company expects that being listed on a junior stock exchange will help reduce the regulatory compliance costs for the company and allow it to preserve capital while it continues to undertake its growth process and path towards financial self-sustainability.”

To view the full press release, visit https://ibn.fm/C4ObD

About Mydecine Innovations Group Inc.

Mydecine Innovations is a publicly traded, prerevenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians’ access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction and PTSD, along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (“AI”). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations. Mydecine developed several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. Mydecine is also developing MYCO-006, which are short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. Mydecine utilizes cutting-edge AI and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make those medications affordable and accessible to the general public upon Health Canada and FDA approval. The Mydecine team is enthusiastic about its mission and is dedicated to creating a positive difference in the lives of others. For more information about the company, please visit www.Mydecine.com.

NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

The Sustainable Green Team (OTCQX: SGTM) has announced the establishment of its wholly owned subsidiary, SGTM-VRM, LLC (“SGTM-VRM”). According to the announcement, the new entity is designed to significantly expand the deployment of VRM Biologik’s intellectual property in the Americas and offer sales to programs and projects globally. In addition, the company announced that it has formed an advisory panel that will seat key staff from VRM Biologik Group and SGTM, who will guide the deployment of large-scale programs globally. “The newly formed wholly owned subsidiary, SGTM-VRM, which now holds the ‘Master Licensee’ for deployment of VRM Biologik’s intellectual property is a testament to the strong relationship between SGTM and VRM Biologik,” said SGTM’s CEO Tony Raynor. “Over the past two years, Ken Bellamy, VRM Biologik’s founder, has worked tirelessly with us to allow HumiSoil(R) and Core Catalyst products to be readily available in and from the USA. I’m excited for the future together with SGTM-VRM.”

To view the full press release, visit https://ibn.fm/awc5U

About Sustainable Green Team Ltd.

The Sustainable Green Team is a leading provider of solutions to improve environmental health and promote sustainable practices. With a focus on innovative products and strategic partnerships, SGTM is dedicated to creating a greener and more sustainable future for generations. Learn more by visiting the company’s website at www.thesustainablegreenteam.com and SGTM’s YouTube Channel.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Hillcrest (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HI) CEO Don Currie recently joined Steve Darling from Proactive to share news the company is receiving support from the government of Canada for a multi-phase demonstration program involving its Hillcrest ZVS inverter in a Hercules recreational e-boat. The program will consist of two phases, starting with testing at the motor supplier’s facility, followed by the integration and demonstration of Hillcrest’s ZVS inverter in a Hercules recreational e-boat. The initiative aims to gather crucial data on continuous power levels of up to 350 kilowatts, which will have a significant impact on Hillcrest’s development programs. Currie clarified that this funding will enhance the demonstration program and provide the company with valuable integration and test data.

To view the full press release, visit https://ibn.fm/1LcAI

About Hillcrest Energy Technologies Ltd.

Hillcrest is a clean technology company focused on providing advanced power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable energy systems. From concept to commercialization, Hillcrest is investing in the development of energy solutions that will power a more sustainable and electrified future. Hillcrest is publicly traded on the CSE under the symbol HEAT, on the OTCQB Venture Market as HLRTF and on the Frankfurt Exchange as 7HI. For more information, please visit www.HillcrestEnergy.tech.

NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

LQWD (TSX.V: LQWD) (OTCQB: LQWDF) has announced that it is leveraging artificial intelligence (“AI”) technology to optimize and automate the company’s Lightning Network channels for peak performance and efficiency. On the heels of nine months of collecting data from LQWD’s nodes throughout eighteen countries and combining TensorFlow Framework with Nvidia’s AI technology, LQWD’s team is capturing the significant potential of AI technology. “With the integration of AI technology, LQWD solidifies its position as a trailblazer in the Bitcoin Lightning Network community,” said LQWD’s CEO Shone Anstey. “This advancement in operations has pushed the LQWD- Canada node to a top 5 ranking of nodes on the Lightning Network. We will continue to leverage AI-powered automation to promote transaction growth.”

To view the full press release, visit https://ibn.fm/DnBAz

LQWD Technologies Corp.

LQWD is a Lightning Network Liquidity Provider focused on developing payment infrastructure and solutions accelerating the global mega trend of Bitcoin adoption through the Lightning Network. LQWD also owns Bitcoin that is used as an operating asset establishing nodes and payment channels on the Lightning Network.

NOTE TO INVESTORS: The latest news and updates relating to LQWD are available in the company’s newsroom at https://ibn.fm/LQWDF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Standard Lithium (TSX.V: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial lithium company, has appointed Michael (“Mike”) Barman as chief development officer, effective Oct. 8, 2023. Barman brings almost two decades of experience in roles advising senior executives and their boards. Most recently, he served as managing director in investment banking at Stifel Nicolaus Canada Inc. (formerly GMP Securities L.P.). In that position, he played a key advisory role on more than 30 mergers, acquisitions and corporate transactions with a combined value totaling more than $22 billion. In addition, facilitated more than 80 public and private financings, raising more than $10 billion in equity and debt capital. “Mike adds extensive and impressive commercial experience to our leadership team with his long career in advising and financing companies in the energy transition sector,” said Standard Lithium CEO and director Robert Mintak in the press release. “His appointment is timely given the late-stage discussions underway with a broad array of industry leaders and household names on our portfolio of projects.”

To view the full press release, visit https://ibn.fm/9tfNt

About Standard Lithium Ltd.

Standard Lithium is a leading near-commercial lithium development company with a portfolio of projects in process. The company’s flagship projects, Phase 1A Project and the South West Arkansas Project, are located in southwestern Arkansas in the heart of the Smackover Foundation. The company is focused on producing lithium from brine using direct lithium extraction (“DLE”) across approximately 180,000 acres of leases from these two projects. Standard Lithium is a leading near-commercial lithium development company focused on the sustainable development of a portfolio of lithium-brine bearing properties in the United States. The company prioritizes brine projects characterized by the highest-grade resources, robust infrastructure, skilled labor and streamlined permitting. The company aims to achieve sustainable, commercial-scale lithium production via the application of a scalable and fully integrated DLE and purification process. The company’s flagship projects, the Phase 1A Project and the South West Arkansas Project, are located on the Smackover Formation in southern Arkansas near the Louisiana state line, a region with a long-standing and established brine processing industry. The company has also identified a number of highly prospective lithium brine project areas in the Smackover Formation in east Texas and has begun an extensive brine leasing program in the key project areas. In addition, SLI has an interest in certain mineral leases located in the Mojave Desert in San Bernardino County, California. For more information about the company, please visit www.StandardLithium.com.

NOTE TO INVESTORS: The latest news and updates relating to SLI are available in the company’s newsroom at https://ibn.fm/SLI

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will be presenting at the upcoming Jefferies Biotech CNS/Neuro Summit. Held for the first time, the summit is scheduled for Oct. 11–12, 2023, in New York City. According to the announcement, company representatives will be presenting at the event; the Vistagen Therapeutics presentation is slated to begin at 12 p.m. PT on Oct. 12. In addition, Vistagen representatives will be available for one-on-one meetings throughout the event.

To view the full press release, visit https://ibn.fm/mSLuV

About Vistagen Therapeutics Inc.

Vistagen Therapeutics is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing therapeutics with the potential to be faster acting and with fewer side effects and safety concerns than treatments that are currently available for treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including fasedienol (“PH94B”), itruvone (“PH10”), PH15, PH80 and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral prodrug antagonist of the N-methyl-D-aspartate receptor (“NMDAR”). Pherines are neuroactive nasal sprays designed with an innovative proposed mechanism of action that activates chemosensory neurons in the nasal cavity and can beneficially impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression and several other CNS disorders. For more information about the company, please visit www.Vistagen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, has announced a new strategic partnership with a top five national employee benefits consulting firm, to become the preferred digital health and chronic condition solution partner for its national employer clients. According to the announcement, the firm selected Dario for its proven ability to deliver meaningful engagement and improved clinical results at a lower cost than competitors. Under the agreement, Dario becomes the digital chronic condition management option for the firm’s clients looking to implement a solution to address diabetes, pre-diabetes, hypertension, musculoskeletal and behavioral health needs. “As employers increasingly turn to their trusted consultants to help navigate decisions on digital health solutions, having the right partners becomes even more important,” said Rick Anderson, president of Dario. “We’re proud to announce this new partnership with such a respected leader in the industry and excited to work with their team of trusted advisors to help their clients get the best possible solution for their needs.”

To view the full press release, visit https://ibn.fm/8sVeb

About DarioHealth Corp.

DarioHealth is a leading digital health company, revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Its platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. Dario’s user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to health care. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do. Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO  

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

DoubleDown Interactive (NASDAQ: DDI), a leading developer and publisher of digital games on mobile and web-based platforms, today announced a planned donation of $10,000 to the American Cancer Society (“ACS”) in honor of Breast Cancer Awareness Month. According to the update, DoubleDown Casino, which is played daily by millions of fans worldwide on both desktop and mobile devices, will invite players to engage with and show support for the charitable donation by taking part in a play-to-enter giveaway on Oct. 11, 2023. The “Spin for a Cure” event offers players the chance to express their enthusiasm for helping the American Cancer Society and to learn more about the organization’s important work. “DoubleDown Interactive has long been committed to honoring Breast Cancer Awareness Month with our charitable outreach,” said In Keuk Kim, CEO of DoubleDown. “We are proud to support the American Cancer Society.”

To view the full press release, visit https://ibn.fm/Pc4un

About DoubleDown Interactive Co. Ltd.

DoubleDown Interactive is a leading developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players, bringing authentic Vegas entertainment to players around the world through an online social casino experience. Its flagship title, DoubleDown Casino, has been a fan-favorite game on leading social and mobile platforms for years, entertaining millions of players worldwide with a lineup of classic and modern games.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Aditxt (NASDAQ: ADTX) is a global innovation activation company focused on the discovery, development and deployment of technologies that monitor and modulate the immune system. The company today announced that it has appointed Ernie Lee to serve as the chief executive officer of its wholly owned subsidiary Pearsanta Inc. The appointment intends to accelerate the commercial launch of Test2Treat.me, an end-to-end, business-to-business (“B2B”) and direct-to-consumer (“DTC”) clinical diagnostic testing services platform for retail pharmacies, physician practices, employee benefit programs, and consumers. “Naming Ernie as CEO of Pearsanta is a crucial initial step in our plan to scale the company and capitalize on global opportunities,” said Amro Albanna, co-founder, chairman and CEO of Aditxt. “With Ernie at the helm, we believe that Test2Treat.me has the potential to quickly fill a void in the healthcare market for DTC point-of-care testing and treatment.”

To view the full press release, visit https://ibn.fm/sxpwk

About Aditxt Inc.

Aditxt is a global innovation company focused on discovering, developing and deploying technologies that monitor and modulate the immune system. The company is headquartered in Richmond, Virginia, with operations in Mountain View, California, and Melville, New York. Aditxt’s mission of “Making Promising Innovations Possible, Together” is defined by its growing ecosystem of research institutions, global industry partners and shareholders who inform and inspire its mission. Aditxt’s diverse innovation portfolio includes: Adimune(TM), Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity and allergies; Adivir(TM), Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta(TM), Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at their CLIA certified and CAP accredited clinical laboratory based in Richmond, Virginia. For more information, visit the company’s websites at www.Aditxt.com, www.Adimune.com and www.Pearsanta.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

GolfLync, seen as one of the hottest and fastest growing new golf apps in social media, is pleased to announce a partnership with golfing sensation Eliezer Paul-Gindiri, nicknamed “Snappy Gilmore,” whose distinctive single-handed golf swing stunned the golfing world in 2021. GolfLync’s many features, including its trademarked Virtual Golf Clubs(TM) (“VGC”), private feeds, group chats, and personalized golf experiences, set it apart as the go-to social network for golfers of all levels.

As Snappy Gilmore stated “Finding players is easy on GolfLync. Having my own Virtual Club allowing my followers access is…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

Contact:
Investor Relations
[email protected]
(480) 877-9953

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary oral appliances for the treatment of breathing-related sleep disorders. The company today announced its entry into an exclusive distribution agreement with NOUM DMCC (“Noum”), a Dubai-based company focused on diagnostic testing and treatment product distribution for healthcare providers and hospital networks treating obstructive sleep apnea patients throughout the Middle East-North Africa (“MENA”) region. “Our expansion into the MENA region represents yet another important milestone for Vivos. To date we have been more focused on our domestic expansion opportunities in the United States and been less focused on international expansion,” said Kirk Huntsman, chairman and CEO of Vivos. “However, given Noum’s excellent track record representing SleepImage in the region, we could not pass up this opportunity as we knew that we now had a partner with the resources and expertise to support our expansion into the Middle East region of the globe. We look forward to supporting Noum in their efforts to train and support doctors treating breathing and sleep disorder patients using Vivos products and technology, as well as the revenue opportunities for Vivos from this collaboration.”

To view the full press release, visit https://ibn.fm/DFehf

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild-to-moderate OSA. It has proven effective in approximately 40,000 patients treated worldwide by more than 1,800 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using The Vivos Method. For more information, visit www.Vivos.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Bruush Oral Care (NASDAQ: BRSH), a company committed to inspiring confidence through brighter smiles and better oral health, has entered into a securities purchase agreement with an institutional investor. The company anticipates the purchase agreement to total an estimated $5 million in gross proceeds before deducting standard fees and other offering expenses. According to the announcement, the company plans to issue 79,724 common shares, a prefunded common share purchase warrant to purchase 7,181,146 common shares, and a common share purchase warrant to purchase 8,350,000 common shares — all as part of the private placement. The company noted that the common warrants and prefunded warrants have a five-year term from the date of issuance, with the closing of the private placement planned on or about Oct. 3, 2023. EF Hutton, division of Benchmark Investments LLC. is acting as the exclusive placement agent for the private placement.

To view the full press release, visit https://ibn.fm/jkBvx

About Bruush Oral Care Inc.

Bruush Oral Care is on a mission to inspire confidence through brighter smiles and better oral health. Founded in 2018, Brüush is an oral care company that is disrupting the space by reducing the barriers between consumers and access to premium oral care products. The company is an e-commerce business with a product portfolio that currently consists of a sonic-powered electric toothbrush kit and brush head refills. Brüush has developed a product to make upgrading to an electric brush appealing with three core priorities in mind: (i) a high-quality electric toothbrush at a more affordable price than a comparable electric toothbrush from the competition; (ii) a sleek, countertop-friendly design; and (iii) a convenient brush head refill subscription program that eliminates the frustrating experience of purchasing replacement brush heads at the grocery/drug store. The company is rooted in building a brand that creates relevant experiences and content, with the goal of becoming the go-to oral care brand for millennials and Generation Z. For further information about the company, visit www.Bruush.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

• RJDG acquires, manages, and grows assets in three stable sectors: healthcare billing and payment technology, specialty construction, and environmental services
• Assets include ioSoft Inc., Silex Holdings Inc., and Earthlinc Environmental Solutions
• RJDG’s management team leverages decades of operational, management, and financial expertise to restructure, manage, and position assets for long-term returns

Diversification is one of the keys to investment success in volatile markets. With that principle in focus, the management team at RJD Green (OTC: RJDG), a holding company, is currently building wealth and generating long-term returns in several resilient markets: healthcare billing and payment technology, specialty construction, and environmental services.

RJDG’s portfolio currently comprises ioSoft Inc., Silex Holdings Inc., and Earthlinc Environmental Solutions. ioSoft Inc., a part of RJDG’s healthcare division, offers secure payment technologies and cloud-based software for healthcare payers and providers. ioSoft’s modular SaaS software seamlessly integrates with…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to RJDG are available in the company’s newsroom at https://ibn.fm/RJDG

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has announced that its CEO Doug Drysdale will present at the Jefferies Inaugural Biotech CNS/Neuro Summit. The event is slated to take place in New York City on Oct. 11-12, 2023, with Drysdale’s presentation webcast live at 12:00 p.m. ET on Oct. 11. Interested parties should visit https://ibn.fm/2QS68 to register and access the webcast. The archived webcast will also be available on the company’s investor relations website.

To view the full press release, visit https://ibn.fm/cyuNh

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN